|
|
(N=228)
|
(N=256)
|
(N=484)
|
|
|
GERD at One Month
|
|
Resolved
|
0 (0%)
|
8 (3.1%)
|
8 (1.7%)
|
0.001
|
|
Improved
|
7 (3.1%)
|
51 (19.9%)
|
58 (12.0%)
|
|
|
Worse
|
1 (0.4%)
|
2 (0.8%)
|
3 (0.6%)
|
|
|
No change
|
33 (14.5%)
|
113 (44.1%)
|
146 (30.2%)
|
|
|
New diagnosis
|
4 (1.8%)
|
0 (0%)
|
4 (0.8%)
|
|
|
Not applicable
|
134 (58.8%)
|
22 (8.6%)
|
156 (32.2%)
|
|
|
Missing
|
49 (21.5%)
|
60 (23.4%)
|
109 (22.5%)
|
|
|
GERD at Third Month
|
|
Resolved
|
4 (1.8%)
|
8 (3.1%)
|
12 (2.5%)
|
0.001
|
|
Improved
|
8 (3.5%)
|
58 (22.7%)
|
66 (13.6%)
|
|
|
Worse
|
0 (0%)
|
3 (1.2%)
|
3 (0.6%)
|
|
|
No change
|
39 (17.1%)
|
89 (34.8%)
|
128 (26.4%)
|
|
|
New diagnosis
|
4 (1.8%)
|
0 (0%)
|
4 (0.8%)
|
|
|
Not applicable
|
110 (48.2%)
|
18 (7.0%)
|
128 (26.4%)
|
|
|
Missing
|
63 (27.6%)
|
80 (31.3%)
|
143 (29.5%)
|
|
|
GERD at Sixth Month
|
|
Resolved
|
6 (2.6%)
|
25 (9.8%)
|
31 (6.4%)
|
0.001
|
|
Improved
|
6 (2.6%)
|
34 (13.3%)
|
40 (8.3%)
|
|
|
Worse
|
0 (0%)
|
2 (0.8%)
|
2 (0.4%)
|
|
|
No change
|
26 (11.4%)
|
71 (27.7%)
|
97 (20.0%)
|
|
|
New diagnosis
|
1 (0.4%)
|
0 (0%)
|
1 (0.2%)
|
|
|
Not applicable
|
87 (38.2%)
|
18 (7.0%)
|
105 (21.7%)
|
|
|
Missing
|
102 (44.7%)
|
106 (41.4%)
|
208 (43.0%)
|
|
|
GERD at Year
|
|
Resolved
|
8 (3.5%)
|
22 (8.6%)
|
30 (6.2%)
|
0.001
|
|
Improved
|
6 (2.6%)
|
27 (10.5%)
|
33 (6.8%)
|
|
|
Worse
|
0 (0%)
|
5 (2.0%)
|
5 (1.0%)
|
|
|
No change
|
9 (3.9%)
|
53 (20.7%)
|
62 (12.8%)
|
|
|
New diagnosis
|
1 (0.4%)
|
0 (0%)
|
1 (0.2%)
|
|
|
Not applicable
|
62 (27.2%)
|
10 (3.9%)
|
72 (14.9%)
|
|
|
Missing
|
142 (62.3%)
|
139 (54.3%)
|
281 (58.1%)
|
|
|
Reflux at One Year
|
|
No
|
0 (0%)
|
0 (0%)
|
0 (0%)
|
NA
|
|
Yes
|
50 (21.9%)
|
68 (26.6%)
|
118 (24.4%)
|
|
|
Missing
|
178 (78.1%)
|
188 (73.4%)
|
366 (75.6%)
|
|
|
Reflux at 2nd Year
|
|
No
|
0 (0%)
|
0 (0%)
|
0 (0%)
|
NA
|
|
Yes
|
12 (5.3%)
|
27 (10.5%)
|
39 (8.1%)
|
|
|
Missing
|
216 (94.7%)
|
229 (89.5%)
|
445 (91.9%)
|
|
|
Reflux Meds at 3 Months Post-Qx
|
|
Lost to follow up
|
25 (11.0%)
|
30 (11.7%)
|
55 (11.4%)
|
0.979
|
|
MgOH
|
7 (3.1%)
|
3 (1.2%)
|
10 (2.1%)
|
|
|
Nil
|
18 (7.9%)
|
20 (7.8%)
|
38 (7.9%)
|
|
|
PPI
|
169 (74.1%)
|
193 (75.4%)
|
362 (74.8%)
|
|
|
PPI, MgOH
|
9 (3.9%)
|
8 (3.1%)
|
17 (3.5%)
|
|
|
PPH, MgOH
|
0 (0%)
|
1 (0.4%)
|
1 (0.2%)
|
|
|
PPI, Zantac
|
0 (0%)
|
1 (0.4%)
|
1 (0.2%)
|
|
|
Reflu Meds at 6 Months Post-Qx
|
|
Lost to follow up
|
76 (33.3%)
|
77 (30.1%)
|
153 (31.6%)
|
0.871
|
|
MgOH
|
3 (1.3%)
|
3 (1.2%)
|
6 (1.2%)
|
|
|
Nil
|
49 (21.5%)
|
45 (17.6%)
|
94 (19.4%)
|
|
|
PPI
|
98 (43.0%)
|
125 (48.8%)
|
223 (46.1%)
|
|
|
PPI, MgOH
|
2 (0.9%)
|
6 (2.3%)
|
8 (1.7%)
|
|
|
Reflux Meds at 12 Months Post-Qx
|
|
Lost to follow up
|
114 (50.0%)
|
107 (41.8%)
|
221 (45.7%)
|
0.785
|
|
MgOH
|
1 (0.4%)
|
5 (2.0%)
|
6 (1.2%)
|
|
|
Nil
|
66 (28.9%)
|
78 (30.5%)
|
144 (29.8%)
|
|
|
PPI
|
44 (19.3%)
|
62 (24.2%)
|
106 (21.9%)
|
|
|
PPI, MgOH
|
3 (1.3%)
|
3 (1.2%)
|
6 (1.2%)
|
|
|
Pepcidine
|
0 (0%)
|
1 (0.4%)
|
1 (0.2%)
|
|